Regulations

FDA Issues Warning Letter to Art of Beauty Company Over CGMPs

Cites five issues within the facility.

The US Food and Drug Administration (FDA) issued a Warning Letter to Art of Beauty Company, Inc., Bedford, OH. According to FDA, the facility is not compliance with Current Good Manufacturing Practice regulations for finished pharmaceuticals. According to FDA: AoB’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 21...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters